IRCT20170809035597N4尚未招募Unknown
Efficacy, safety, satisfaction, toleberility and treatment duribility of long-pulsed Nd:YAG 1064 nm laser compared with fractional Q-switch Nd:YAG 1064 nm laser in the treatment of active acne vulgaris in patients under treatment with azithromycine: An assessor-analyst-blinded split-body triple-arms randomized controlled clinical trial
试验速览
- 阶段
- Unknown
- 状态
- 尚未招募
- 入组人数
- 20
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 15 years 至 50 years（—）
- 性别
- All
入选标准
- •Patient between 15 and 50 years old
- •Patients with a confirmed diagnosis of facial active acne
- •During the last 3 months, the patient has not received any treatment for the disease.
- •Lack of underlying disease
- •The patient's cooperation in carrying out therapeutic interventions and referring for all therapeutic sessions
排除标准
- •The patient has been treated for acne in the last three months
- •The presence of a serious underlying disease in the person
研究者
相似试验
进行中（未招募）
1 期
Study to understand if inclisiran is better than a placebo at lowering LDL-cholesterol, is safe and can have an impact on patient quality of life, when given along with other lipid lowering medications.MedDRA version: 21.0Level: LLTClassification code 10020604Term: HypercholesterolemiaSystem Organ Class: 100000004861HypercholesterolemiaEUCTR2021-003759-40-ESovartis Pharma AG1,760
进行中（未招募）
1 期
Study to understand if inclisiran is better than a placebo at lowering LDL-cholesterol, is safe and can have an impact on patient quality of life, when given along with other lipid lowering medications.MedDRA version: 21.0Level: LLTClassification code 10020604Term: HypercholesterolemiaSystem Organ Class: 10027433 - Metabolism and nutrition disordersHypercholesterolemiaEUCTR2021-003759-40-DEovartis Pharma AG1,760
进行中（未招募）
1 期
Study to understand if inclisiran is better than a placebo at lowering LDL-cholesterol, is safe and can have an impact on patient quality of life, when given along with other lipid lowering medications.MedDRA version: 21.0Level: LLTClassification code 10020604Term: HypercholesterolemiaSystem Organ Class: 100000004861HypercholesterolemiaEUCTR2021-003759-40-LVovartis Pharma AG1,760
进行中（未招募）
1 期
Study to understand if inclisiran is better than a placebo at lowering LDL-cholesterol, is safe and can have an impact on patient quality of life, when given along with other lipid lowering medications.MedDRA version: 21.0Level: LLTClassification code 10020604Term: HypercholesterolemiaSystem Organ Class: 100000004861HypercholesterolemiaEUCTR2021-003759-40-EEovartis Pharma AG1,760
招募中
1 期
Study to understand if inclisiran is better than a placebo at lowering LDL-cholesterol, is safe and can have an impact on patient quality of life, when given along with other lipid lowering medications.HypercholesterolemiaMedDRA version: 21.0Level: LLTClassification code 10020604Term: HypercholesterolemiaSystem Organ Class: 10027433 - Metabolism and nutrition disordersEUCTR2021-003759-40-BGovartis Pharma AG1,760